State of Wyoming Buys New Shares in Jazz Pharmaceuticals PLC $JAZZ

State of Wyoming purchased a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,208 shares of the specialty pharmaceutical company’s stock, valued at approximately $417,000.

A number of other hedge funds have also recently bought and sold shares of the stock. LRI Investments LLC bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter worth approximately $38,000. Danske Bank A S acquired a new position in Jazz Pharmaceuticals during the third quarter worth $40,000. Geneos Wealth Management Inc. increased its holdings in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 137 shares during the last quarter. Caitong International Asset Management Co. Ltd raised its position in Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 332 shares in the last quarter. Finally, Leonteq Securities AG bought a new stake in Jazz Pharmaceuticals during the fourth quarter worth $50,000. 89.14% of the stock is currently owned by institutional investors.

Insider Activity

In other Jazz Pharmaceuticals news, Director Rick E. Winningham sold 2,741 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.57, for a total transaction of $662,143.37. Following the completion of the sale, the director directly owned 9,567 shares in the company, valued at $2,311,100.19. This trade represents a 22.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction that occurred on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. The trade was a 2.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 13,098 shares of company stock valued at $3,131,906. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on JAZZ shares. Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $265.00 to $285.00 and gave the company an “overweight” rating in a research note on Tuesday, July 14th. Morgan Stanley restated an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Canaccord Genuity Group assumed coverage on Jazz Pharmaceuticals in a report on Thursday, July 16th. They set a “buy” rating and a $290.00 price target for the company. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Finally, TD Cowen upped their price objective on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $259.06.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $253.87 on Monday. The firm has a market capitalization of $15.95 billion, a PE ratio of -12,687.16, a PEG ratio of 0.22 and a beta of 0.32. The company’s 50-day moving average is $237.37 and its 200-day moving average is $203.44. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $256.75. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The company had revenue of $1.07 billion during the quarter. Equities analysts forecast that Jazz Pharmaceuticals PLC will post 21.9 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.